Key takeaways from ASCO® 2026
July 16, 2026 | ASCO, Congress, Pharma, healthcare, oncology
Following ASCO® 2026, Inizio’s experts have shared their perspectives across three thought leadership articles, each exploring a different aspect of what this year’s congress revealed for pharmaceutical organisations. Together, they examine the evolving role of congresses, from experience design and technology to strategy, measurement and commercial impact.
ASCO® 2026 showcased groundbreaking oncology science, innovative congress experiences, and new approaches to engaging healthcare professionals. It also highlighted how pharma organizations are rethinking congress strategy, experience design, measurement, and commercialization to maximize impact.
Explore the latest four expert articles from across Inizio, each offering practical insights into creating more engaging experiences, using technology more effectively, delivering measurable congress outcomes, and accelerating commercial success.
- What the best congress experiences got right at ASCO® 2026: What separated the most memorable congress experiences from the rest? Simon Davenport, Global Head of Environments, Inizio Engage, shares three principles that consistently stood out on the exhibition floor, from creating a clear scientific narrative to designing interactions that genuinely add value and building experiences that accommodate different HCP journeys.
- What ASCO® 2026 revealed about the future of pharma congress engagement: From AI-powered experiences and immersive environments to tactile, low-tech activations, Nick Bellomo, VP of Experience and Technology, Inizio Medical, explores the engagement innovations that captured attention at ASCO® 2026 and explains why the best experiences balance creativity with purposeful scientific communication.
- ASCO® 2026: Why a connected approach is key to congress success: As congresses become increasingly complex and investment continues to grow, measuring impact has never been more important. Lynsey Holbrook, Global Client Development Director, Inizio Engage, discusses why connecting strategy, execution and measurement is essential for delivering meaningful scientific and commercial outcomes.
- ASCO® 2026: Four trends reshaping oncology commercialization: Oncology innovation is accelerating, bringing greater commercial complexity. Jo Ann Saitta, Head of Data & AI, Inizio Ignite, explores four trends shaping commercialization, from AI and patient intelligence to connected data, and explains why turning fragmented real-world data into faster, smarter decisions is becoming a competitive advantage.
This content was provided by Inizio
Company Details
Latest Content from Inizio
Pharma leadership strategies for talent, AI adoption, and continuous learning
In a recent interview with Pharma Exec, Elaine Ferguson, Global President of Inizio Medical, explores how pharma leadership can support talent development, use AI to augment the workforce, encourage continuous…
Smarter science, sharper strategy: Expert insights from ASCO® 2026
As the oncology landscape continues to evolve, life sciences organizations face a growing challenge: how do you communicate increasingly complex science in a way that creates meaningful engagement?
Intelligent Commercialization™ across the pharma lifecycle
Pharma teams are under growing pressure to navigate launch complexity, identify risks earlier, and engage HCPs more effectively.
Four steps to a smarter congress strategy: A practical guidebook
This guidebook explores how Intelligent Congress helps pharma teams create more coordinated, measurable, and impactful congress strategies.
Infographic: Are data blind spots putting your launch at risk?
Commercial pharma launches depend on confident, evidence-led decisions. Yet many launch teams are still working with fragmented data spread across multiple systems, making it difficult to understand market readiness, prioritize…
Key takeaways from ASCO® 2026
Following ASCO® 2026, Inizio’s experts have shared their perspectives across three thought leadership articles, each exploring a different aspect of what this year’s congress revealed for pharmaceutical organisations. Together, they…
Webcast | Smarter science, sharper strategy: Expert perspectives from ASCO® 2026
Key insights from ASCO® 2026, including oncology trends, scientific highlights, and strategies for smarter congress engagement.
From activity to impact: 5 takeaways from MAPS Americas 2026
Across sessions, panels, and conversations on the ground in Denver, there was a noticeable shift in both mindset and momentum. Many of the themes discussed in previous years are now…
Inizio launches Intelligent Congress: Turning medical event investment into measurable impact
Inizio, the global commercialization partner to the health and life sciences industry, today announced the launch of Intelligent Congress – a connected, end-to-end solution designed to help pharma organizations maximize…
Inizio Unveils Next-Generation Hub Services at Asembia 2026, Setting a New Standard in Patient Access
Integrated capabilities combining advanced analytics, pharmacy, and specialized talent to improve access, affordability, and adherence